Ilva G Iriarte1, Mark S George2,3. 1. Department of Psychiatry, Medical University of South Carolina (MUSC), Charleston, SC, USA. ilva.iriarte@scdmh.org. 2. Department of Psychiatry, Medical University of South Carolina (MUSC), Charleston, SC, USA. 3. Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Abstract
PURPOSE OF REVIEW: This article aims to review select applications of Transcranial Magnetic Stimulation (TMS) that have significant relevance in geriatric psychiatry. RECENT FINDINGS: Small study sizes and parameter variability limit the generalizability of many TMS studies in geriatric patients. Additionally, geriatric patients have unique characteristics that can moderate the efficacy of TMS. Nonetheless, several promising experimental applications in addition to the FDA-approved indication for major depression have emerged. Cognitive impairment, neuropathic pain, and smoking cessation are experimental applications with special significance to the elderly. Cognitive impairment has been researched the most in this population and evidence thus far suggests that TMS has potential therapeutic benefit. There is also evidence to suggest benefit from TMS for neuropathic pain and smoking cessation in working age adults. TMS is consistently reported as a safe and well-tolerated treatment modality with no adverse cognitive side effects. TMS is a safe treatment modality that can be effective for certain applications in the elderly. Additional research that specifically includes older subjects is needed to replicate findings and to optimize treatment protocols for this population.
PURPOSE OF REVIEW: This article aims to review select applications of Transcranial Magnetic Stimulation (TMS) that have significant relevance in geriatric psychiatry. RECENT FINDINGS: Small study sizes and parameter variability limit the generalizability of many TMS studies in geriatric patients. Additionally, geriatric patients have unique characteristics that can moderate the efficacy of TMS. Nonetheless, several promising experimental applications in addition to the FDA-approved indication for major depression have emerged. Cognitive impairment, neuropathic pain, and smoking cessation are experimental applications with special significance to the elderly. Cognitive impairment has been researched the most in this population and evidence thus far suggests that TMS has potential therapeutic benefit. There is also evidence to suggest benefit from TMS for neuropathic pain and smoking cessation in working age adults. TMS is consistently reported as a safe and well-tolerated treatment modality with no adverse cognitive side effects. TMS is a safe treatment modality that can be effective for certain applications in the elderly. Additional research that specifically includes older subjects is needed to replicate findings and to optimize treatment protocols for this population.
Authors: Agustin G Yip; Mark S George; Aron Tendler; Yiftach Roth; Abraham Zangen; Linda L Carpenter Journal: Brain Stimul Date: 2017-03-10 Impact factor: 8.955
Authors: F S Bersani; A Minichino; P G Enticott; L Mazzarini; N Khan; G Antonacci; R N Raccah; M Salviati; R Delle Chiaie; G Bersani; P B Fitzgerald; M Biondi Journal: Eur Psychiatry Date: 2012-05-03 Impact factor: 5.361
Authors: Christine A Conelea; Noah S Philip; Agustin G Yip; Jennifer L Barnes; Matthew J Niedzwiecki; Benjamin D Greenberg; Audrey R Tyrka; Linda L Carpenter Journal: J Affect Disord Date: 2017-03-29 Impact factor: 4.839
Authors: Max M Klein; Roi Treister; Tommi Raij; Alvaro Pascual-Leone; Lawrence Park; Turo Nurmikko; Fred Lenz; Jean-Pascal Lefaucheur; Magdalena Lang; Mark Hallett; Michael Fox; Merit Cudkowicz; Ann Costello; Daniel B Carr; Samar S Ayache; Anne Louise Oaklander Journal: Pain Date: 2015-09 Impact factor: 7.926
Authors: S M Romanella; D Roe; E Tatti; D Cappon; R Paciorek; E Testani; A Rossi; S Rossi; E Santarnecchi Journal: Sleep Med Date: 2020-05-30 Impact factor: 3.492